A comparative evaluation of adverse platelet outcomes among veterans' affairs patients receiving linezolid or vancomycin

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 727-735

  Patel, Nimish ^a   Vandewall, Hillary ^a   Tristani, Linda ^b   Rivera, Antonio ^b   Woo, Benjamin ^a   Dihmess, Amanda ^a   Li, Hsin K ^a   Smith, Raymond ^b   Lodise, Thomas P ^a,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Glycopeptides; Oxazolidinones; Pharmacoepidemiology; Thrombocytopenia

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VETERAN;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BLOOD PLATELETS; COHORT STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEW YORK; OXAZOLIDINONES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84863074623     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr522     Document Type: Article

References (34)

1. Zyvox - Full Prescribing Information. New York, NY: Pfizer Inc., 2010.
2. Rao N, Ziran BH, Wagener MM et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38: 1058-64.
3. Nasraway SA, Shorr AF, Kuter DJ et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37: 1609-16.
4. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
5. Kohno S, Yamaguchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361-9.
6. Wunderink RG, Mendelson MH, Somero MS et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134: 1200-7.
7. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53: 335-44.
8. Takahashi Y, Takesue Y, Nakajima K et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17: 382-7.
9. Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20: 292-307.
10. Newland AC. The problem of thrombocytopenia and its management. Anticancer Drugs 1995; 6 Suppl 5: 65-73.
11. Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21: 685-96, vi.
12. Reddy JC, Shuman MA, Aster RH. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med 2004; 164: 218-20.
13. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-7.
14. Warkentin TE, Roberts RS, Hirsh J et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-24.
15. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 2008; 133 Suppl: 340S-80S.
16. Greinacher A, Eichler P, Lietz T et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106: 2921-2.
17. Greinacher A, Farner B, Kroll H et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-5.
18. Pouplard C, May MA, Iochmann S et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-6.
19. Von Drygalski A, Curtis BR, Bougie DW et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356: 904-10.
20. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
21. Tisdale J. Drug-Induced Diseases: Prevention, Detection, and Management. Bethesda, MD: American Society of Health-System Pharmacists, 2005.
22. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997; 52: 183-9.
23. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
24. Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-23.
25. Soriano A, Martinez JA, Mensa J et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30: 368-73.
26. Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application to breast cancer data. Biometrics 1978; 34: 57-67.
27. Greenland S, Rothman K. Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2008.
28. Kalil AC, Murthy MH, Hermsen ED et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38: 1802-8.
29. Kenney B, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008; 19: 379-83.
30. O'Donnell E, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. Am J Hematol 2007; 82: 1122.
31. Peel RK, Sykes A, Ashmore S et al. A case of immune thrombocytopenic purpura from intraperitoneal vancomycin use. Perit Dial Int 2003; 23: 506-8.
32. Howard CE, Adams LA, Admire JL et al. Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Ann Pharmacother [1997;] 31: 315-8.
33. Mizon P, Kiefel V, Mannessier L et al. Thrombocytopenia induced by vancomycin-dependent platelet antibody. Vox Sang 1997; 73: 49-51.
34. Levi M. Platelets in sepsis. Hematology 2005; 10 Suppl 1: 129-31.